TargetBeta
CDK4
cyclin dependent kinase 4 · also PSK-J3 · Cyclin dependent kinases
12 programs in company-led studies act on CDK4, from 11 companies: 4 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| abemaciclibrule | Eli Lilly | phase 4 | 4914 running | CDK6 | NCIt |
| palbociclibrule | Pfizer | phase 4 | 364 running | CCND1, CDK6 | ChEMBL |
| trilaciclibrule | Pharmacosmos | phase 4 | 143 running | CDK6 | NCIt |
| atirmociclib | Pfizer | phase 3 | 1710 running | – | the company's pipeline |
| HRS-6209 | Jiangsu HengRui Medicine | phase 3 | 77 running | – | the company's pipeline |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 115 running | CDK2, CDK6 | the company's pipeline |
| CDK4 Inhibitor BGB-43395rule | BeOne Medicines | phase 3 | 42 running | – | NCIt |
| narazaciclibrule | Hangzhou Hanx Biopharmaceuticals | phase 2 | 43 running | CDK6, NUAK1 | NCIt |
| vustanaciclib | Regor Pharmaceuticals | phase 2 | 33 running | CDK2, CDK6 | a judged reading |
| CG-7321rule | Chengdu Cynogen Bio-pharmaceutical Tech. | phase 1 | 11 running | CDK2 | the studies' text |
| nkt5097 cdk2rule | NiKang Therapeutics | phase 1 | 11 running | CDK2 | the studies' text |
| TSL2109rule | China Resources Pharmaceutical Group | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Breast Neoplasms, 8 programs
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Liposarcoma, 2 programs
- Neoplasm Metastasis, 2 programs
- Prostatic Neoplasms, 2 programs
- Sarcoma, Ewing, 2 programs
- Triple Negative Breast Neoplasms, 2 programs
- Carcinoma, Renal Cell, 1 program
- Carcinoma, Transitional Cell, 1 program
- Colorectal Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026abemaciclib · Eli Lilly · phase 4 · NCT07818967
- Nov 22, 2026CDK4 Inhibitor BGB-43395 · BeOne Medicines · phase 3 · NCT07820891
- Dec 2026HRS-6209 · Jiangsu HengRui Medicine · phase 3 · NCT06974929
- Dec 2026culmerciclib · Sino Biopharmaceutical · phase 3 · NCT05780567
- Dec 22, 2026palbociclib · Pfizer · phase 4 · NCT05468697
- Dec 30, 2026vustanaciclib · Regor Pharmaceuticals · phase 2 · NCT06299124
- Dec 31, 2026narazaciclib · Hangzhou Hanx Biopharmaceuticals · phase 2 · NCT06703255
- Dec 31, 2026TSL2109 · China Resources Pharmaceutical Group · phase 1 · NCT07514065
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.